title: Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases.
abstract: 123I-Iodolisuride has high specific affinity for binding on dopamine D2 receptors in the striatum and has been used in a few single photon emission computed tomography (SPECT) studies of extrapyramidal disorders. The diagnosis of Parkinson's disease (PD) is very difficult in the first 5 years of evolution, with 15-25% false positive diagnoses. The aim of this study was therefore to determine the value of iodolisuride SPECT in discriminating Parkinson's from the most frequent Parkinson-plus syndromes (PPS). Seventeen patients with an extrapyramidal syndrome had a SPECT examination 1 h after injection of 180-185 MBq of 123I-iodolisuride. They were followed under dopaminergic treatment for at least 2 years. After 2 years, they were separated in two groups according to specific clinical criteria and sensitivity to dopaminergic treatment: nine patients had PD (age = 59.8+/-8.8 years; Hoehn and Yahr = 1.8+/-0.7; evolution = 4.3+/-3 years) and eight had PPS (age = 71.6+/-7.3 years; Hoehn and Yahr = 2.9+/-2.0; evolution = 4.1+/-1.5 years). The binding potential of iodolisuride in the striatum was assessed by considering the striatum (S)/occipital lobe (O) ratio at the pseudo-equilibrium 1 h after injection. The S/O ratio was statistically different between PD and PPS (1.97+/-0.3 vs. 1.65+/-0.2 (P<0.02)). Iodolisuride SPECT could differentiate both groups with a sensitivity of 88.8% and a specificity of 75%. Iodolisuride is a good specific D2 receptor ligand for SPECT and complements specific clinical criteria for the diagnosis of Parkinson's disease and differentiation between different extrapyramidal disorders.
authors.affiliation: Department of Nuclear Medicine and INSERM U316, University Hospital of Tours, France. c.prunier@bretonneau.chu-tours.fr
authors.forename: C
authors.initials: C
authors.lastname: Prunier
authors.forename: F
authors.initials: F
authors.lastname: Tranquart
authors.forename: J P
authors.initials: JP
authors.lastname: Cottier
authors.forename: B
authors.initials: B
authors.lastname: Giraudeau
authors.forename: S
authors.initials: S
authors.lastname: Chalon
authors.forename: D
authors.initials: D
authors.lastname: Guilloteau
authors.forename: B
authors.initials: B
authors.lastname: De Toffol
authors.forename: F
authors.initials: F
authors.lastname: Chossat
authors.forename: A
authors.initials: A
authors.lastname: Autret
authors.forename: J C
authors.initials: JC
authors.lastname: Besnard
authors.forename: J L
authors.initials: JL
authors.lastname: Baulieu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001480:Basal Ganglia Diseases / Q000000981:diagnostic imaging*; D003342:Corpus Striatum / Q000000981:diagnostic imaging*; D003937:Diagnosis, Differential; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008090:Lisuride / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000000981:diagnostic imaging; D019636:Neurodegenerative Diseases / Q000000981:diagnostic imaging*; D010300:Parkinson Disease / Q000000981:diagnostic imaging*; D020734:Parkinsonian Disorders / Q000000981:diagnostic imaging; D017448:Receptors, Dopamine D2 / Q000032:analysis*; D013494:Supranuclear Palsy, Progressive / Q000000981:diagnostic imaging; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D007457:Iodine Radioisotopes; D017448:Receptors, Dopamine D2; C075786:iodolisuride; D008090:Lisuride